05:37 PM EST, 12/10/2024 (MT Newswires) -- Acelyrin ( SLRN ) said late Tuesday it will not make any additional internal investment in developing izokibep after a phase 2b/3 trial in treating noninfectious, nonanterior uveitis failed to meet its primary endpoint.

Uveitis is a form of eye inflammation. The study didn't meet the primary endpoint of a statistically significant improvement in time to treatment failure compared with placebo as measured by treatment failure rates at 24 weeks, the company said. Statistical significance wasn't reached for any secondary endpoint, while no clinical benefit was observed, Acelyrin ( SLRN ) said.

The company said it will continue to focus on executing its late-stage development program for lonigutamab in thyroid eye disease.

Acelyrin ( SLRN ) shares slumped 15% in after-hours activity.

Price: 3.44, Change: -0.62, Percent Change: -15.27